ABCG51 Antibody

What is ABCG5 and why is it significant in research?

ABCG5 (ATP-binding cassette, sub-family G, member 5) is a half-transporter that forms a functional heterodimer with ABCG8. This complex mediates the excretion of sterols from liver and intestine, playing a critical role in cholesterol homeostasis. Researchers study ABCG5 because dysfunction of this transporter is associated with sitosterolemia, an autosomal disease characterized by impaired elimination of dietary sterols and increased risk of cardiovascular disease. Loss-of-function variants of ABCG5 or ABCG8 cause sitosterolemia, while gain-of-function mutations are associated with gallstone disease . Studying ABCG5 helps understand cholesterol homeostasis mechanisms and potential therapeutic interventions for related disorders.

Which experimental applications are suitable for ABCG5 antibody?

ABCG5 antibodies are validated for multiple applications including:

Researchers should always titrate the antibody in their specific testing system to obtain optimal results as performance can be sample-dependent .

What is the predicted molecular weight of ABCG5 and how does it appear on Western blots?

The calculated molecular weight of ABCG5 is 72 kDa, but the observed molecular weight on Western blots typically ranges from 68 kDa to 72 kDa . This slight variance may reflect post-translational modifications or differential processing of the protein depending on tissue source or experimental conditions. When troubleshooting unexpected band patterns, researchers should consider these natural variations.

How should researchers select appropriate positive controls for ABCG5 detection?

Based on validation data, researchers should consider these positive controls for ABCG5 detection:

When establishing a new experimental system, it's advisable to include at least one validated positive control alongside experimental samples to confirm antibody functionality.

What are the critical aspects of ABCG5/G8 heterodimer formation that influence antibody selection?

When selecting antibodies for studying ABCG5, researchers must consider that ABCG5 functions as a heterodimer with ABCG8. This dimeric arrangement creates unique epitopes that may be absent in individual monomers. The heterodimer possesses a unique dimer interface between the nucleotide-binding domains (NBDs) of opposing transporters, featuring an ordered network of salt bridges between the conserved NPXDFXXD motif . This interface serves as a pivot point that may be essential for the transport cycle.

When selecting antibodies, researchers should determine whether they need to detect:

• The ABCG5 monomer regardless of dimerization status

• The ABCG5/G8 heterodimer specifically

• Functional domains involved in transport activity

Some antibodies may recognize epitopes that become masked upon heterodimer formation, while others might specifically recognize heterodimer-specific conformations.

How do monoclonal antibodies modulate ABCG5/G8 ATPase activity?

Monoclonal antibodies can have opposite effects on ABCG5/G8 ATPase activity based on their epitope binding. Research has demonstrated two distinct mechanisms:

• Inhibitory antibodies (e.g., mAb 2E10): This antibody inhibits ATPase activity with an IC50 of 49.4 nM by interacting with both the RecA and helical domains of the NBD from ABCG8. The total buried surface area between Fab 2E10 and ABCG8 is approximately 1640 Å2. By binding simultaneously to both domains, the antibody restricts the relative motion between these domains, hindering the completion of the ATP hydrolysis cycle .

• Stimulatory antibodies (e.g., mAb 11F4): This antibody potentiates ATPase activity with an EC50 of 67.2 nM, potentially by stabilizing the NBD dimer formation .

These differential effects provide valuable tools for researchers to manipulate ABCG5/G8 activity in experimental settings and gain insights into the coupling mechanism between NBD and TMD domains.

What are the recommended antigen retrieval methods for ABCG5 detection in IHC?

For optimal ABCG5 detection in immunohistochemistry applications, antigen retrieval is critical. The recommended primary method is:

• TE buffer at pH 9.0

Alternatively, if suboptimal results are obtained:

• Citrate buffer at pH 6.0 can be used as an alternative

The choice between these methods may depend on tissue type, fixation method, and embedding procedure. Researchers should validate both methods with appropriate controls when establishing a new IHC protocol for ABCG5 detection.

How can structural insights from cryo-EM studies inform antibody-based research on ABCG5/G8?

Cryo-EM studies have revealed critical structural features of ABCG5/G8 that can inform antibody-based experimental approaches:

• Epitope accessibility: The cryo-EM structure of ABCG5/G8 at 3.3Å resolution reveals accessible epitopes on the NBD domains that can be targeted by antibodies without disrupting physiological function .

• Functional domain interactions: Understanding the coupling between transmembrane domains (TMDs) and nucleotide-binding domains (NBDs) helps researchers design antibodies that can modulate specific aspects of transporter function .

• Conformational states: The structure reveals that the helical domain rotates approximately 35 degrees around the RecA domains upon ATP binding to form the closed NBD dimer. Antibodies targeting specific conformational states can be designed to stabilize or inhibit these transitions .

• Novel therapeutic targets: The structural data identifies potential epitopes for therapeutic interventions, particularly in treating conditions like sitosterolemia .

Researchers developing or using antibodies against ABCG5/G8 should consider these structural features when interpreting results or designing new experimental approaches.

What computational approaches are emerging for antibody design targeting transporters like ABCG5?

While not specifically developed for ABCG5 antibodies, cutting-edge computational approaches for antibody design show promise for targeting membrane transporters like ABCG5/G8. New score-based diffusion generative models guided by evolutionary, physical, and geometric constraints are demonstrating success in antibody design. These approaches:

• Leverage pre-trained protein language models as priors for evolutionarily plausible antibodies

• Introduce training objectives for geometric and physical constraints like van der Waals forces

• Jointly model discrete sequence space and SE(3) structure space

These computational approaches could potentially accelerate the development of highly specific antibodies against ABCG5 or the ABCG5/G8 complex, particularly for difficult-to-target epitopes or to achieve specific functional modulation.

How can researchers validate the specificity of ABCG5 antibody in their experiments?

Validating antibody specificity is crucial for reliable results. For ABCG5 antibody, consider these validation strategies:

• Positive and negative controls:

  • Use known positive controls such as Caco-2 cells, HepG2 cells, and liver tissue samples

  • Include negative controls lacking ABCG5 expression

• Knockout/knockdown validation:

  • Compare detection in wild-type versus ABCG5 knockout or knockdown samples

  • This provides the strongest evidence of specificity

• Peptide competition assay:

  • Pre-incubate antibody with immunizing peptide before application

  • Signal should be reduced or eliminated if the antibody is specific

• Molecular weight verification:

  • Confirm detection at the expected molecular weight (68-72 kDa for ABCG5)

  • Check for any non-specific bands

• Multiple antibody validation:

  • Verify results using multiple antibodies targeting different ABCG5 epitopes

  • Consistent results strengthen validity

What resources can researchers use to find validated ABCG5 antibodies?

Researchers seeking validated ABCG5 antibodies can leverage several specialized resources:

• Antibody search engines: These allow comparison of antibodies from multiple vendors simultaneously .

• Antibody data repositories: These share validation and experimental data to help determine if an antibody fits your experiment. Particularly useful repositories include:

  • General repositories that cover all targets and applications

  • Repositories specializing in human proteins for immunoblot, IP, and IF

  • Those focused on healthy human cells for imaging applications

  • Repositories for cancer or immune cell research

• Literature citation search: Examining publications that have successfully used ABCG5 antibodies provides real-world validation. The ABCG5 antibody (27722-1-AP) has been cited in 34 publications for Western blot applications and 1 publication for IHC , providing a foundation of validated experimental conditions.

When selecting an antibody, researchers should review available validation data carefully to ensure compatibility with their specific experimental conditions and applications.

How should researchers approach contradictory results when using different ABCG5 antibodies?

When faced with contradictory results using different ABCG5 antibodies, researchers should consider:

• Epitope differences: Different antibodies may target distinct epitopes on ABCG5. Some epitopes might be:

  • Masked in certain conformational states

  • Affected by post-translational modifications

  • Involved in protein-protein interactions (especially with ABCG8)

  • Accessible only in certain experimental conditions

• Antibody characteristics:

  • Polyclonal vs. monoclonal specificity differences

  • Possible cross-reactivity with ABCG8 or other ABC transporters

  • Application-specific performance variations

• Experimental validation approach:

  • Implement additional controls to determine which antibody provides accurate results

  • Use complementary techniques (e.g., mass spectrometry) to verify protein identity

  • Consider knockout/knockdown validation to definitively establish specificity

• Reconciliation strategies:

  • Map the recognized epitopes where possible

  • Determine if differences reflect biologically meaningful states

  • Consider that both results may be correct but reflecting different aspects of ABCG5 biology

Understanding the basis for contradictory results can sometimes lead to new biological insights about ABCG5 function or regulation.

How can antibodies be used to study the coupling mechanism between NBD and TMD in ABCG5/G8?

Antibodies provide powerful tools for studying the coupling mechanism between nucleotide-binding domains (NBDs) and transmembrane domains (TMDs) in ABCG5/G8:

• Conformational-specific antibodies: Using antibodies that recognize specific conformational states can help track the movements between domains during the transport cycle. For example, antibodies like mAb 2E10 that simultaneously bind to the RecA and helical domains can capture specific transitional states .

• Domain-specific modulators: Antibodies that modulate ATPase activity, such as mAb 11F4 (stimulatory) and mAb 2E10 (inhibitory), provide tools to manipulate specific steps in the coupling mechanism and observe downstream effects on transport .

• Structural probing: Antibody binding can stabilize transient conformations for structural studies. The cryo-EM structure of ABCG5/G8 was determined at 3.3Å resolution using Fab fragments, revealing unique features of the NBD dimer interface that may serve as pivot points during the transport cycle .

• Functional dissection: By targeting specific epitopes with known functional relevance, researchers can dissect which structural elements are critical for different aspects of the transport cycle.

These approaches can help answer key questions about how ATP hydrolysis energy in the NBD is coupled to sterol substrate transport across cell membranes through the TMD.

What are the experimental considerations when studying ABCG5 in disease models of sitosterolemia?

When investigating ABCG5 in sitosterolemia disease models, researchers should consider:

• Genetic validation: Confirm that disease models contain loss-of-function variants in ABCG5 or ABCG8 genes that accurately reflect the genetic basis of human sitosterolemia .

• Antibody selection concerns:

  • Choose antibodies that can detect mutant ABCG5 variants

  • Consider whether antibodies recognize epitopes affected by disease-causing mutations

  • Validate antibody performance specifically in disease model tissues

• Phenotypic characterization:

  • Monitor plasma phytosterol levels as a key biomarker

  • Assess for development of tendon xanthomas

  • Evaluate cardiovascular disease risk markers

• Transport activity assays:

  • Develop assays to measure sterol efflux capacity

  • Compare wild-type vs. mutant ABCG5/G8 activity

  • Assess how different mutations affect the coupling between ATP hydrolysis and transport

• Therapeutic intervention studies:

  • Use antibodies as tools to modulate ABCG5/G8 activity

  • Evaluate potential for antibody-based therapeutics targeting specific functional domains

These considerations ensure that antibody-based research on ABCG5 in sitosterolemia models yields physiologically relevant insights that may translate to therapeutic applications.